首页 > 最新文献

Clinical chemistry最新文献

英文 中文
Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease. 批准首例镰状细胞病 CRISPR-Cas9 基因编辑疗法。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae038
Sean T Campbell
{"title":"Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease.","authors":"Sean T Campbell","doi":"10.1093/clinchem/hvae038","DOIUrl":"10.1093/clinchem/hvae038","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"70 10","pages":"1298"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity. 关于新生儿筛查阳性和 CFTR 复合杂合体情况下的阴性汗液氯化物检测的评论。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae117
Mark A Cervinski
{"title":"Commentary on Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity.","authors":"Mark A Cervinski","doi":"10.1093/clinchem/hvae117","DOIUrl":"10.1093/clinchem/hvae117","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"70 10","pages":"1205-1206"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity. 新生儿筛查阳性和 CFTR 复合杂合体情况下的阴性汗液氯化物检测。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae102
Lucille De Maria, Marion Marlinge, Melisande Baravalle, Jean-Christophe Dubus, Julien Fromonot
{"title":"Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity.","authors":"Lucille De Maria, Marion Marlinge, Melisande Baravalle, Jean-Christophe Dubus, Julien Fromonot","doi":"10.1093/clinchem/hvae102","DOIUrl":"10.1093/clinchem/hvae102","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"70 10","pages":"1202-1205"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosing Myocardial Injury in an Acute Chest Pain Cohort; Long-Term Prognostic Implications of Cardiac Troponin T and I. 诊断急性胸痛队列中的心肌损伤;心肌肌钙蛋白 T 和 I 的长期预后意义。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae110
Nasir Saeed, Ole-Thomas Steiro, Jørund Langørgen, Hilde L Tjora, Rune O Bjørneklett, Øyvind Skadberg, Vernon V S Bonarjee, Øistein R Mjelva, Tone M Norekvål, Trude Steinsvik, Kjell Vikenes, Torbjørn Omland, Kristin M Aakre

Background: There are limited data regarding the utility of follow-up cardiac troponin (cTn) measurements after admission for acute chest pain and how long-term stability of myocardial injury and prognostic value differ when using cardiac troponin T (cTnT) or I (cTnI).

Methods: We measured high-sensitivity (hs)-cTnT (Roche Diagnostics) and hs-cTnI (Siemens Healthineers) during hospitalization for acute chest pain and after 3 months. Acute myocardial injury was defined as concentrations > sex-specific upper reference limit (URL) during hospitalization and ≤URL at 3-months. Chronic myocardial injury (CMI) was defined as concentrations > URL at both time points. Patients were followed from the 3-month sampling point for a median of 1586 (IQR 1161-1786) days for a primary composite endpoint of all-cause mortality, myocardial infarction (MI), revascularization, and heart failure, and a secondary endpoint of all-cause mortality.

Results: Among 754 patients, 33.8% (hs-cTnT) and 19.2% (hs-cTnI) had myocardial injury during hospitalization. The rate of CMI was 5 times higher by hs-cTnT (20%) assay than hs-cTnI (4%), while acute myocardial injury was equally common; 14% (hs-cTnT) and 15% (hs-cTnI), respectively (6% and 5% when excluding index non-ST-elevation MI (NSTEMI). For hs-cTnT, peak index concentration, 3-month concentration and classification of CMI predicted the primary endpoint; hazard ratios (HRs) 1.38 (95% CI 1.20-1.58), 2.34 (1.70-3.20), and 2.31 (1.30-4.12), respectively. For hs-cTnI, peak index concentration predicted the primary endpoint; HR 1.14 (1.03-1.25). This association was nonsignificant after excluding index NSTEMI.

Conclusions: Acute myocardial injury is equally frequent, whereas CMI is more prevalent using hs-cTnT assay than hs-cTnI. Measuring hs-cTnT 3 months after an acute chest pain episode could assist in further long-term risk assessment. ClinicalTrials.gov Registration Number: NCT02620202.

背景:关于急性胸痛入院后随访心肌肌钙蛋白(cTn)测量的效用,以及使用心肌肌钙蛋白 T(cTnT)或 I(cTnI)时心肌损伤的长期稳定性和预后价值有何不同,相关数据十分有限:我们在急性胸痛住院期间和 3 个月后测量了高敏 (hs)-cTnT (罗氏诊断公司)和 hs-cTnI(西门子健康公司)。急性心肌损伤的定义是:住院期间浓度>特定性别参考上限 (URL),且 3 个月后≤URL。慢性心肌损伤(CMI)的定义是两个时间点的浓度均大于 URL。从3个月的取样点开始,对患者进行了中位数为1586天(IQR 1161-1786)的随访,以确定全因死亡率、心肌梗死(MI)、血管重建和心力衰竭的主要复合终点以及全因死亡率的次要终点:在 754 名患者中,33.8%(hs-cTnT)和 19.2%(hs-cTnI)在住院期间出现心肌损伤。hs-cTnT(20%)检测的CMI率是hs-cTnI(4%)的5倍,而急性心肌损伤同样常见;分别为14%(hs-cTnT)和15%(hs-cTnI)(如果不包括指数非ST段抬高型心肌梗死(NSTEMI),则分别为6%和5%)。对于 hs-cTnT,指数峰值浓度、3 个月浓度和 CMI 分类可预测主要终点;危险比 (HR) 分别为 1.38(95% CI 1.20-1.58)、2.34(1.70-3.20)和 2.31(1.30-4.12)。对于 hs-cTnI,峰值指数浓度可预测主要终点;HR 为 1.14(1.03-1.25)。排除指数NSTEMI后,这一关联并不显著:急性心肌损伤的发生率相同,但使用 hs-cTnT 检测的 CMI 比 hs-cTnI 更常见。在急性胸痛发作 3 个月后测量 hs-cTnT,有助于进一步进行长期风险评估。ClinicalTrials.gov 注册号:NCT02620202:NCT02620202。
{"title":"Diagnosing Myocardial Injury in an Acute Chest Pain Cohort; Long-Term Prognostic Implications of Cardiac Troponin T and I.","authors":"Nasir Saeed, Ole-Thomas Steiro, Jørund Langørgen, Hilde L Tjora, Rune O Bjørneklett, Øyvind Skadberg, Vernon V S Bonarjee, Øistein R Mjelva, Tone M Norekvål, Trude Steinsvik, Kjell Vikenes, Torbjørn Omland, Kristin M Aakre","doi":"10.1093/clinchem/hvae110","DOIUrl":"10.1093/clinchem/hvae110","url":null,"abstract":"<p><strong>Background: </strong>There are limited data regarding the utility of follow-up cardiac troponin (cTn) measurements after admission for acute chest pain and how long-term stability of myocardial injury and prognostic value differ when using cardiac troponin T (cTnT) or I (cTnI).</p><p><strong>Methods: </strong>We measured high-sensitivity (hs)-cTnT (Roche Diagnostics) and hs-cTnI (Siemens Healthineers) during hospitalization for acute chest pain and after 3 months. Acute myocardial injury was defined as concentrations > sex-specific upper reference limit (URL) during hospitalization and ≤URL at 3-months. Chronic myocardial injury (CMI) was defined as concentrations > URL at both time points. Patients were followed from the 3-month sampling point for a median of 1586 (IQR 1161-1786) days for a primary composite endpoint of all-cause mortality, myocardial infarction (MI), revascularization, and heart failure, and a secondary endpoint of all-cause mortality.</p><p><strong>Results: </strong>Among 754 patients, 33.8% (hs-cTnT) and 19.2% (hs-cTnI) had myocardial injury during hospitalization. The rate of CMI was 5 times higher by hs-cTnT (20%) assay than hs-cTnI (4%), while acute myocardial injury was equally common; 14% (hs-cTnT) and 15% (hs-cTnI), respectively (6% and 5% when excluding index non-ST-elevation MI (NSTEMI). For hs-cTnT, peak index concentration, 3-month concentration and classification of CMI predicted the primary endpoint; hazard ratios (HRs) 1.38 (95% CI 1.20-1.58), 2.34 (1.70-3.20), and 2.31 (1.30-4.12), respectively. For hs-cTnI, peak index concentration predicted the primary endpoint; HR 1.14 (1.03-1.25). This association was nonsignificant after excluding index NSTEMI.</p><p><strong>Conclusions: </strong>Acute myocardial injury is equally frequent, whereas CMI is more prevalent using hs-cTnT assay than hs-cTnI. Measuring hs-cTnT 3 months after an acute chest pain episode could assist in further long-term risk assessment. ClinicalTrials.gov Registration Number: NCT02620202.</p>","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1241-1255"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Commentary on Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity. 关于新生儿筛查阳性和 CFTR 复合杂合体情况下的阴性汗液氯化物检测的评论。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae121
Adrienne Savant
{"title":"Commentary on Negative Sweat Chloride Testing in the Setting of a Positive Newborn Screen and CFTR Compound Heterozygosity.","authors":"Adrienne Savant","doi":"10.1093/clinchem/hvae121","DOIUrl":"10.1093/clinchem/hvae121","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":"70 10","pages":"1206-1207"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Results in Laboratory Medicine. 实验室医学的关键成果
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae120
Kobe Truijens, Glynis Frans, Pieter Vermeersch

Background: Timely and accurate notification of critical results is crucial in laboratory medicine and mandated by accreditation standards like ISO15189. Alert lists do, however, vary widely and clinical laboratories typically rely on a combination of in-house agreed and/or literature-based critical values. Communication by phone is still the preferred method of notification, but digital communication could help improve communication of critical results.

Content: We review the available evidence concerning critical result thresholds and critical result notification practices. The evidence is ranked using an adaptation of the Stockholm Hierarchy. In addition, we propose an evidence-based list of critical result thresholds for hospitalized patients that laboratories can use as a starter list and further customize based on the clinical needs of their patient population.

Summary: A clear distinction between critical results and significantly abnormal results is essential for effective and timely healthcare interventions. Implementation of a policy using differentiated thresholds taking into account individual patient characteristics and how fast medical attention is needed, and the use alternative communication methods could enhance communication efficiency and reduce notification fatigue.

背景:及时、准确地通报关键结果对实验室医学至关重要,也是 ISO15189 等认可标准所要求的。然而,警报列表的差异很大,临床实验室通常依赖于内部商定和/或基于文献的临界值的组合。电话沟通仍是首选的通知方式,但数字通信有助于改善关键结果的沟通:内容:我们回顾了有关临界结果阈值和临界结果通知方法的现有证据。内容:我们回顾了有关临界结果阈值和临界结果通知做法的现有证据,并采用斯德哥尔摩层次理论对证据进行了排序。此外,我们还提出了一份以证据为基础的住院患者危急结果阈值清单,实验室可将其作为入门清单,并根据患者群体的临床需求进行进一步定制。摘要:明确区分危急结果和严重异常结果对于有效、及时的医疗干预至关重要。考虑到患者的个体特征和需要尽快就医的程度,实施一项使用差异化阈值的政策,并使用其他沟通方法,可以提高沟通效率并减少通知疲劳。
{"title":"Critical Results in Laboratory Medicine.","authors":"Kobe Truijens, Glynis Frans, Pieter Vermeersch","doi":"10.1093/clinchem/hvae120","DOIUrl":"10.1093/clinchem/hvae120","url":null,"abstract":"<p><strong>Background: </strong>Timely and accurate notification of critical results is crucial in laboratory medicine and mandated by accreditation standards like ISO15189. Alert lists do, however, vary widely and clinical laboratories typically rely on a combination of in-house agreed and/or literature-based critical values. Communication by phone is still the preferred method of notification, but digital communication could help improve communication of critical results.</p><p><strong>Content: </strong>We review the available evidence concerning critical result thresholds and critical result notification practices. The evidence is ranked using an adaptation of the Stockholm Hierarchy. In addition, we propose an evidence-based list of critical result thresholds for hospitalized patients that laboratories can use as a starter list and further customize based on the clinical needs of their patient population.</p><p><strong>Summary: </strong>A clear distinction between critical results and significantly abnormal results is essential for effective and timely healthcare interventions. Implementation of a policy using differentiated thresholds taking into account individual patient characteristics and how fast medical attention is needed, and the use alternative communication methods could enhance communication efficiency and reduce notification fatigue.</p>","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1220-1230"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of Age for the Diagnostic and Prognostic Value of Cardiac Troponin T and I. 年龄对心肌肌钙蛋白 T 和 I 诊断和预后价值的影响
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae107
Rasmus Bo Hasselbalch, Philip Andreas Schytz, Martin Schultz, Caroline Sindet-Pedersen, Jonas Henrik Kristensen, Nina Strandkjær, Sophie Sander Knudsen, Mia Pries-Heje, Manan Pareek, Kristian H Kragholm, Nicholas Carlson, Morten Schou, Mikkel Porsborg Andersen, Henning Bundgaard, Christian Torp-Pedersen, Kasper Karmark Iversen

Background: The influence of age on cardiac troponin is unclear and may vary between cardiac troponin T (cTnT) and I (cTnI). We aimed to compare the impact of age on the diagnostic and prognostic utility of cTnT and cTnI.

Methods: This Danish nationwide, register-based cohort study included patients with at least one cardiac troponin (cTn) measurement from 2009 through June 2022, stratified into decades of age. We used peak cTn concentration during admission, dichotomized as positive/negative and normalized to the 99th percentile. Receiver operating characteristics for myocardial infarction (MI) and logistic regression were used to estimate the odds ratio (OR) for mortality at 1 year.

Results: We included 541 817 patients; median age 66 years (interquartile range [IQR] 51-77) and 256 545 (47%) female. A total of 40 359 (7.4%) had an MI, and 59 800 (14.1%) patients died within 1 year of admission. The predictive ability of both cTns for MI were highest for patients 30 to 50 years. This was most pronounced for cTnT, the specificity of which fell from 83% among patients 40 to 49 years to 4% for patients ≥90 years. The prognostic ability of both cTns for 1-year mortality declined with age. cTnT had stronger prognostic ability for all age-groups; OR for a positive cTnT 28.4 (95% CI, 20.1-41.0) compared with 9.4 (95% CI, 5.0-16.7) for cTnI among patients <30 years.

Conclusions: The predictive and prognostic ability of cTnT and cTnI declined with age. cTnT had a low specificity for MI in elderly patients. However, cTnT was the strongest prognostic marker among all age groups.

背景:年龄对心肌肌钙蛋白的影响尚不明确,而且心肌肌钙蛋白T(cTnT)和心肌肌钙蛋白I(cTnI)之间可能存在差异。我们旨在比较年龄对 cTnT 和 cTnI 诊断和预后效用的影响:这项以登记为基础的丹麦全国性队列研究纳入了从 2009 年到 2022 年 6 月至少进行过一次心肌肌钙蛋白(cTn)测量的患者,并将其按年龄分为不同组别。我们使用入院时的 cTn 峰值浓度,将其分为阳性/阴性,并归一化为第 99 百分位数。使用心肌梗死(MI)的受体操作特征和逻辑回归估算1年死亡率的几率比(OR):我们共纳入了 541 817 名患者;中位年龄为 66 岁(四分位数间距 [IQR] 51-77),女性患者为 256 545 人(47%)。共有 40 359 名患者(7.4%)发生了心肌梗死,59 800 名患者(14.1%)在入院一年内死亡。两种 cTns 对心肌梗死的预测能力在 30 至 50 岁的患者中最高。这一点在 cTnT 中最为明显,其特异性从 40 至 49 岁患者的 83% 降至≥90 岁患者的 4%。cTnT 对所有年龄组的预后能力都更强;cTnT 阳性的 OR 为 28.4(95% CI,20.1-41.0),而 cTnI 阳性的 OR 为 9.4(95% CI,5.0-16.7):cTnT 和 cTnI 的预测和预后能力随着年龄的增长而下降。然而,在所有年龄组中,cTnT 是最强的预后标志物。
{"title":"Implications of Age for the Diagnostic and Prognostic Value of Cardiac Troponin T and I.","authors":"Rasmus Bo Hasselbalch, Philip Andreas Schytz, Martin Schultz, Caroline Sindet-Pedersen, Jonas Henrik Kristensen, Nina Strandkjær, Sophie Sander Knudsen, Mia Pries-Heje, Manan Pareek, Kristian H Kragholm, Nicholas Carlson, Morten Schou, Mikkel Porsborg Andersen, Henning Bundgaard, Christian Torp-Pedersen, Kasper Karmark Iversen","doi":"10.1093/clinchem/hvae107","DOIUrl":"10.1093/clinchem/hvae107","url":null,"abstract":"<p><strong>Background: </strong>The influence of age on cardiac troponin is unclear and may vary between cardiac troponin T (cTnT) and I (cTnI). We aimed to compare the impact of age on the diagnostic and prognostic utility of cTnT and cTnI.</p><p><strong>Methods: </strong>This Danish nationwide, register-based cohort study included patients with at least one cardiac troponin (cTn) measurement from 2009 through June 2022, stratified into decades of age. We used peak cTn concentration during admission, dichotomized as positive/negative and normalized to the 99th percentile. Receiver operating characteristics for myocardial infarction (MI) and logistic regression were used to estimate the odds ratio (OR) for mortality at 1 year.</p><p><strong>Results: </strong>We included 541 817 patients; median age 66 years (interquartile range [IQR] 51-77) and 256 545 (47%) female. A total of 40 359 (7.4%) had an MI, and 59 800 (14.1%) patients died within 1 year of admission. The predictive ability of both cTns for MI were highest for patients 30 to 50 years. This was most pronounced for cTnT, the specificity of which fell from 83% among patients 40 to 49 years to 4% for patients ≥90 years. The prognostic ability of both cTns for 1-year mortality declined with age. cTnT had stronger prognostic ability for all age-groups; OR for a positive cTnT 28.4 (95% CI, 20.1-41.0) compared with 9.4 (95% CI, 5.0-16.7) for cTnI among patients <30 years.</p><p><strong>Conclusions: </strong>The predictive and prognostic ability of cTnT and cTnI declined with age. cTnT had a low specificity for MI in elderly patients. However, cTnT was the strongest prognostic marker among all age groups.</p>","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1231-1240"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Troponin I or T for the Diagnosis of Myocardial Infarction and Prediction of Outcomes-Does It Matter? 用于诊断心肌梗死和预测预后的心肌肌钙蛋白 I 或 T--重要吗?
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae123
Ziwen Li, Jasper Boeddinghaus, Nicholas L Mills
{"title":"Cardiac Troponin I or T for the Diagnosis of Myocardial Infarction and Prediction of Outcomes-Does It Matter?","authors":"Ziwen Li, Jasper Boeddinghaus, Nicholas L Mills","doi":"10.1093/clinchem/hvae123","DOIUrl":"10.1093/clinchem/hvae123","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1197-1199"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DPP3 in Cardiogenic Shock. 心源性休克中的 DPP3。
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae058
Allan S Jaffe, Leslie J Donato
{"title":"DPP3 in Cardiogenic Shock.","authors":"Allan S Jaffe, Leslie J Donato","doi":"10.1093/clinchem/hvae058","DOIUrl":"10.1093/clinchem/hvae058","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1200-1201"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Failure of Serum Immunofixation Electrophoresis to Detect Intact Monoclonal IgD Lambda Unraveled by Mass Spectrometry. 质谱法揭示血清免疫固定电泳检测完整单克隆 IgD Lambda 失败的原因
IF 7.1 2区 医学 Q1 MEDICAL LABORATORY TECHNOLOGY Pub Date : 2024-10-03 DOI: 10.1093/clinchem/hvae116
Louis Nevejan, Mark Perkins, Martine Vercammen, Thibault Vanhove, Michel Delforge, Xavier Bossuyt
{"title":"Failure of Serum Immunofixation Electrophoresis to Detect Intact Monoclonal IgD Lambda Unraveled by Mass Spectrometry.","authors":"Louis Nevejan, Mark Perkins, Martine Vercammen, Thibault Vanhove, Michel Delforge, Xavier Bossuyt","doi":"10.1093/clinchem/hvae116","DOIUrl":"10.1093/clinchem/hvae116","url":null,"abstract":"","PeriodicalId":10690,"journal":{"name":"Clinical chemistry","volume":" ","pages":"1291-1293"},"PeriodicalIF":7.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1